Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.120
+0.020 (0.95%)
At close: Aug 11, 2026, 4:00 PM EDT
2.070
-0.050 (-2.36%)
Pre-market: Aug 12, 2026, 4:01 AM EDT
Allogene Therapeutics Employees
As of December 31, 2025, Allogene Therapeutics had 152 total employees, including 150 full-time and 2 part-time employees. The number of employees decreased by 77 or -33.62% compared to the previous year.
Employees
152
Change (1Y)
-77
Growth (1Y)
-33.62%
Revenue / Employee
n/a
Profits / Employee
-$1,143,158
Market Cap
731.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 152 | -77 | -33.62% | 150 | 2 |
| Dec 31, 2024 | 229 | -4 | -1.72% | 226 | 3 |
| Dec 31, 2023 | 233 | -128 | -35.46% | 232 | 1 |
| Dec 31, 2022 | 361 | 51 | 16.45% | 359 | 2 |
| Sep 30, 2022 | 356 | 55 | 18.27% | 356 | 0 |
| Jun 30, 2022 | 344 | 59 | 20.70% | 344 | 0 |
| Mar 31, 2022 | 334 | 58 | 21.01% | 334 | 0 |
| Dec 31, 2021 | 310 | 45 | 16.98% | 308 | 2 |
| Sep 30, 2021 | 301 | 37 | 14.02% | 301 | 0 |
| Jun 30, 2021 | 285 | 49 | 20.76% | 285 | 0 |
| Mar 31, 2021 | 276 | 61 | 28.37% | 276 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| REGENXBIO | 371 |
| Phathom Pharmaceuticals | 371 |
| Neurogene | 131 |
| BridgeBio Oncology Therapeutics | 106 |
| Crescent Biopharma | 69 |
| CytomX Therapeutics | 69 |
| AgomAb Therapeutics NV | 62 |
ALLO News
- 7 days ago - Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update - GlobeNewsWire
- 13 days ago - Allogene gets RMAT, Fast Track designations for cemacabtagene ansegedleucel - TheFly
- 13 days ago - Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma - GlobeNewsWire
- 27 days ago - Allogene publishes Phase 1 data in Journal of Clinical Oncology - TheFly
- 27 days ago - Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors - GlobeNewsWire
- 6 weeks ago - Allogene Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Transcripts
- 7 weeks ago - Allogene Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts